OCUL Ocular Therapeutix

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Ocular Therapeutix, Inc. – OCUL

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ocular Therapeutix, Inc. (NASDAQ: OCUL) resulting from allegations that Ocular Therapeutix may have issued materially misleading business information to the investing public.

On May 5, 2017, Ocular Therapeutix disclosed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant, but downplayed any concerns. On July 6, 2017, Seeking Alpha published an article asserting that Ocular Therapeutix’s management has been misleading investors about manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product. On this news, shares of Ocular Therapeutix fell $0.68 per share or over 6% to close at $9.50 per share on July 6, 2017, damaging investors.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Ocular Therapeutix investors. If you purchased shares of Ocular Therapeutix on or before July 6, 2017, please visit the firm’s website at http://www.rosenlegal.com/cases-1158.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
07/07/2017

Underlying

OCULOcular Therapeutix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocular Therapeutix

 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Global Chief Commercial Officer, David W. Robinson. The awards were approved by Ocular’s Board of Directors and were made as inducements material to Mr. Robinson’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive ...

9h / 21m 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commerc...

Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global C...

January 21, 2026 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timel...

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage the 505(b)(2) regulatory pathway for new drug approvals which has the potential to shorten the review timeline for AXPAXLI If approved, AXPAXLI could be the first TKI to be commercialized in wet AMD, with a potential superiority label and best-in-class durability BEDFORD, Mass., Dec. 08, 2025 (GL...

December 8, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement eq...

December 5, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Pha...

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary superiority trials using a novel ordinal diabetic retinopathy severity scale (DRSS) primary endpoint Targeting a broad diabetic retinopathy (DR) label by including patients with non-center-involved diabetic macular edema (non-CI-DME) BEDFORD, Mass., Nov. 24, 2...

November 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch